The decision by the UK electorate on June 23rd to leave the European Union (EU) is likely to have a number of significant consequences for… Read More »Brexit decision is likely to have significant impact on drug development and IP protection.
RegenxBio Inc. (NASDAQ:RGNX), Washington, D.C. and Biogen Inc. (NASDAQ:BIIB), Cambridge, Massachusetts, have announced the completion of an exclusive worldwide research license agreement allowing Biogen to… Read More »RegenxBio and Biogen strike deal on development of therapies for rare vision disorders.
The University of Philadelphia and Biogen Inc. (NASDAQ: BIIB) have announced a collaboration on the development of gene therapies for eye disease, skeletal muscle disorders… Read More »University of Pennsylvania and Biogen Inc strike a deal on gene therapy technologies to include ophthalmology targets.
California-based company Graybug Vision Inc. has announced the closing of a $44.5 million Series B financing to support commercialisation of a novel AMD therapeutic which… Read More »Graybug Vision Inc. raises $44.5M for neovascular AMD therapy that reduces dosing to once every 6 months
Japanese-US gene therapy company Acucela Inc., has annunced the execution of a licensing deal with the University of Manachester, UK. The exclusive deal will provide… Read More »Acucela Inc. licenses human rhodopsin based optogenetic gene therapy from University of Manchester
French gene therapy company GenSight Biologics SA, based in Paris, France, has announced the withdrawal of a planned IPO (initial public offering) on the US… Read More »French ophthalmology company GenSight withdraws from US IPO listing on NASDAQ
Eyevensys S.A.S., a biotech company, founded by Professor Francine Behar-Cohen and colleagues, has announced the receipt of Orphan Drug Designation from the European Medicines Agency… Read More »French biotech company Eyevensys S.A.S. receives European orphan drug designation for non-infectious uveitis product
Avalanche Biotechnologies Inc., (NASDAQ:AAVL), a public biopharmaceutical company based in California with several ophthalmic gene therapy programs in progress, has announced the acquisition of Annapurna… Read More »Avalanche Biotechnologies Inc. acquires French gene therapy company, Annapurna Therapeutics, in share transfer deal
Ocugen Inc., an early stage biopharmaceutical company based in Pennsylvania, has announced the licensing of a clinical stage technology for the treatment of ocular graft… Read More »Ocugen Inc. secures license for ocular graft versus host disease (oGVHD) from Univesrity of Chicago
Ocular Therapeutix Inc. (NASDAQ:OCUL), based in Bedford, Massachusetts, have announced plans for the further clinical development of a novel sustained release travoprost treatment (OTX-TP) for… Read More »Ocular Therapeutix Inc announces further clinical development studies for glaucoma and ocular hypertension treatment